Cambridge-based healthtech company electronRx is planning to launch foneDx at CES 2024 in Las Vegas. foneDx is a technology installed in modern smartphones and using the existing sensor technology, harnesses digital monitoring to measure the user's critical heart and lung health can be monitored at home.
RYO Alexandre / shutterstock.com
2246383179
Las Vegas Convention Center during CES 2023
The vision for the technology is to empower patients and healthcare professionals to manage chronic diseases effectively and lead to better clinical outcomes. Additionally, the data is real-time and invaluable for healthcare providers, pharmaceutical and research organisations, and commercial companies.
foneDx - combined with a user interface app - has many applications across various industries alongside healthcare. electronRx is receiving interest from the pharmaceutical industry, medical research organisations, mobile phone manufacturers, insurance companies, and automated car manufacturers. The company's appearance at CES 2024 will be the first time that technology manufacturers and worldwide business leaders will have the opportunity to experience foneDx and its capabilities first-hand.
Bipin Patel, CEO of electronRx, said: "Our mission is to deliver a democratised and scalable smartphone technology that will use critical digital monitoring in pulmonary and cardiovascular to monitor patient health. Our technology is vigorously tested in healthcare settings in the UK, Japan, and clinics worldwide which has proven the technology's efficacy. We are delighted to have the opportunity to demonstrate it at CES in January. I believe we have created something incredible that could turn millions of smartphones worldwide into efficient, effective, and life-saving health monitors that will improve millions of people's lives through better condition management leading to better, life-saving clinical outcomes. This will change how we think of areas of healthcare, forever."
